Entropy Technologies LP Makes New Investment in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Entropy Technologies LP acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 32,757 shares of the company’s stock, valued at approximately $259,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Gladius Capital Management LP purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth $37,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Amneal Pharmaceuticals in the 4th quarter worth $81,000. Quest Partners LLC purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth $84,000. Janney Montgomery Scott LLC bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth about $121,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth about $169,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Piper Sandler raised their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $7.91 on Friday. The firm has a market capitalization of $2.45 billion, a price-to-earnings ratio of -11.63 and a beta of 1.10. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $9.48. The company has a 50-day moving average of $8.09 and a 200 day moving average of $8.25.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $8.14, for a total value of $651,200.00. Following the completion of the sale, the director now directly owns 1,888,886 shares of the company’s stock, valued at $15,375,532.04. The trade was a 4.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 160,000 shares of company stock valued at $1,292,000 in the last three months. Company insiders own 26.56% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.